| __timestamp | Bausch Health Companies Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 660772000 |
| Thursday, January 1, 2015 | 2682700000 | 736435000 |
| Friday, January 1, 2016 | 2810000000 | 775266000 |
| Sunday, January 1, 2017 | 2582000000 | 860348000 |
| Monday, January 1, 2018 | 2473000000 | 814775000 |
| Tuesday, January 1, 2019 | 2554000000 | 942821000 |
| Wednesday, January 1, 2020 | 2367000000 | 985616000 |
| Friday, January 1, 2021 | 2624000000 | 1061508000 |
| Saturday, January 1, 2022 | 2625000000 | 1190423000 |
| Sunday, January 1, 2023 | 2917000000 | 1254234000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, Bausch Health Companies Inc. and Grifols, S.A. have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bausch Health's SG&A expenses have shown a steady increase, peaking at approximately $2.9 billion in 2023, marking a 44% rise from 2014. In contrast, Grifols, S.A. has seen a more dramatic growth, with expenses nearly doubling from $661 million in 2014 to $1.25 billion in 2023. This divergence highlights differing strategic priorities, with Bausch Health maintaining a consistent growth trajectory, while Grifols, S.A. aggressively expands its market presence. These trends offer a window into the operational focus and market strategies of these pharmaceutical leaders, providing valuable insights for investors and industry analysts alike.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?